aminolevulinic acid has been researched along with Cancer of Cervix in 65 studies
Aminolevulinic Acid: A compound produced from succinyl-CoA and GLYCINE as an intermediate in heme synthesis. It is used as a PHOTOCHEMOTHERAPY for actinic KERATOSIS.
5-aminolevulinic acid : The simplest delta-amino acid in which the hydrogens at the gamma position are replaced by an oxo group. It is metabolised to protoporphyrin IX, a photoactive compound which accumulates in the skin. Used (in the form of the hydrochloride salt)in combination with blue light illumination for the treatment of minimally to moderately thick actinic keratosis of the face or scalp.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate the efficacy of 5-aminolevulinic acid photodynamic therapy (ALA-PDT) in the treatment of high-grade squamous intraepithelial lesions of the cervix (HSIL)." | 8.12 | Topical 5-aminolevulinic acid photodynamic therapy for cervical high-grade squamous intraepithelial lesions. ( Chen, J; Hu, Y; Li, Y; Ma, L; Teng, Y; Xu, Y, 2022) |
| "Patients with cervical LSIL and HPV infection were divided into 3 treatment groups based on their own choice." | 7.30 | The effect of aminolevulinic acid hydrochloride topical powder photodynamic therapy versus nocardia rubra cell wall skeleton and observers group in the treatment of cervical low-grade squamous intraepithelial lesions with human papillomavirus infection: A ( Gong, H; Jiang, S; Nan, X; Pan, X; Tang, L; Zhang, J, 2023) |
| "Cervical high-grade squamous intraepithelial lesions (HSIL), as pre-cancerous lesions, have a 5% chance of progressing to invasive cancer." | 5.72 | The effect of high-risk HPV E6/E7 mRNA on the efficacy of topical photodynamic therapy with 5-aminolevulinic acid for cervical high-grade squamous intraepithelial lesions. ( Cao, L; Qin, L; Shen, Y; Su, Y; Tang, Y; Wang, B; Wang, L; Zhang, L; Zhang, M; Zhang, T; Zhang, Y; Zhou, Y, 2022) |
| "High-risk HPV infection is the main cause of cervical cancer and pre-cancerous lesions." | 5.62 | The effect of local photodynamic therapy with 5-aminolevulinic acid for the treatment of cervical low-grade squamous intraepithelial lesions with high-risk HPV infection: A retrospective study. ( Cheng, M; Di, W; Gu, L; Hong, Z; Qiu, L, 2021) |
| "Progression to high-grade squamous intraepithelial lesion warrants intervention." | 5.62 | The effect of local photodynamic therapy with 5-aminolevulinic acid for the treatment of cervical low-grade squamous intraepithelial lesions with high-risk HPV infection: A retrospective study. ( Cheng, M; Di, W; Gu, L; Hong, Z; Qiu, L, 2021) |
| "80 patients with CINI and HR-HPV infection were selected for the study." | 5.56 | Treatment of HPV Infection-Associated Low Grade Cervical Intraepithelial Neoplasia with 5-Aminolevulinic Acid-Mediated Photodynamic Therapy. ( Cai, Q; Li, D; Lin, L; Shi, L; Xu, Y; Zhang, F, 2020) |
| "To evaluate the efficacy of 5-aminolevulinic acid photodynamic therapy (ALA-PDT) in the treatment of high-grade squamous intraepithelial lesions of the cervix (HSIL)." | 4.12 | Topical 5-aminolevulinic acid photodynamic therapy for cervical high-grade squamous intraepithelial lesions. ( Chen, J; Hu, Y; Li, Y; Ma, L; Teng, Y; Xu, Y, 2022) |
| "Human tumor cells of the lines WiDr (adenocarcinoma of the rectosigmoid colon), NHIK 3025 (carcinoma of the cervix), and V79 Chinese hamster fibroblasts were treated with 5-aminolevulinic acid (ALA) and ALA esterified to C1-C3 and C6-C8 chained aliphatic alcohols (ALA-esters)." | 3.69 | Use of 5-aminolevulinic acid esters to improve photodynamic therapy on cells in culture. ( Anholt, H; Berg, K; Gaullier, JM; Ma, LW; Moan, J; Peng, Q; Selbo, PK, 1997) |
| "Patients with cervical LSIL and HPV infection were divided into 3 treatment groups based on their own choice." | 3.30 | The effect of aminolevulinic acid hydrochloride topical powder photodynamic therapy versus nocardia rubra cell wall skeleton and observers group in the treatment of cervical low-grade squamous intraepithelial lesions with human papillomavirus infection: A ( Gong, H; Jiang, S; Nan, X; Pan, X; Tang, L; Zhang, J, 2023) |
| "Current treatments of high-grade squamous intraepithelial lesion (HSIL) of the cervix are based on invasive surgical interventions, compromising cervical competence and functionality." | 3.11 | Multicentre, prospective, randomised controlled trial to evaluate hexaminolevulinate photodynamic therapy (Cevira) as a novel treatment in patients with high-grade squamous intraepithelial lesion: APRICITY phase 3 study protocol. ( Chen, F; Dannecker, C; Han, L; Hillemanns, P; Lang, J; Mokráš, C; Novák, Z; Sui, L; You, Z; Zhang, Y, 2022) |
| " The most common adverse event was increased vaginal discharge, other side effects include abdominal pain, vulvar pruritus, and vaginal bleeding." | 1.72 | Efficacy and safety of photodynamic therapy mediatied by 5-aminolevulinic acid for the treatment of vaginal high-grade intraepithelial lesions. ( Guo, H; Han, Q; Wu, Z; Zhang, X, 2022) |
| "Photodynamic therapy mediatied by 5-aminolevulinic acid is an effective and safe treatment for vaginal HSIL with minimal side effects." | 1.72 | Efficacy and safety of photodynamic therapy mediatied by 5-aminolevulinic acid for the treatment of vaginal high-grade intraepithelial lesions. ( Guo, H; Han, Q; Wu, Z; Zhang, X, 2022) |
| "Cervical high-grade squamous intraepithelial lesions (HSIL), as pre-cancerous lesions, have a 5% chance of progressing to invasive cancer." | 1.72 | The effect of high-risk HPV E6/E7 mRNA on the efficacy of topical photodynamic therapy with 5-aminolevulinic acid for cervical high-grade squamous intraepithelial lesions. ( Cao, L; Qin, L; Shen, Y; Su, Y; Tang, Y; Wang, B; Wang, L; Zhang, L; Zhang, M; Zhang, T; Zhang, Y; Zhou, Y, 2022) |
| " The adverse reactions after PDT were mild, mainly manifested as increased vaginal secretions or burning/tingling." | 1.72 | Evaluation of the efficacy and safety of 5-aminolevulinic acid-mediated photodynamic therapy in women with high-risk HPV persistent infection after cervical conization. ( Huang, Y; Jia, L; Liu, X; Liu, Y; Wang, L; Zhang, J; Zhang, Y, 2022) |
| "5-Aminolevulinic acid (5-ALA) is a porphyrin-based photosensitizer and has been used for photodynamic therapy of cervical intraepithelial neoplasia (CIN)." | 1.62 | Photodetection and Safety of 5-Aminolevulinic Acid-Induced Porphyrin in Patients With Cervical Intraepithelial Neoplasia. ( Bai, W; Cao, F; Chen, R; Cui, Y; Dong, Y; Shi, Y; Tao, J; Xu, J; Zhao, J; Zhao, X, 2021) |
| " Three adverse events were considered related to the drug; however, these had no significant correlation with the drug concentration or application time." | 1.62 | Photodetection and Safety of 5-Aminolevulinic Acid-Induced Porphyrin in Patients With Cervical Intraepithelial Neoplasia. ( Bai, W; Cao, F; Chen, R; Cui, Y; Dong, Y; Shi, Y; Tao, J; Xu, J; Zhao, J; Zhao, X, 2021) |
| "5-ALA at 10%-30% concentration is safe in patients with CIN." | 1.62 | Photodetection and Safety of 5-Aminolevulinic Acid-Induced Porphyrin in Patients With Cervical Intraepithelial Neoplasia. ( Bai, W; Cao, F; Chen, R; Cui, Y; Dong, Y; Shi, Y; Tao, J; Xu, J; Zhao, J; Zhao, X, 2021) |
| "High-risk HPV infection is the main cause of cervical cancer and pre-cancerous lesions." | 1.62 | The effect of local photodynamic therapy with 5-aminolevulinic acid for the treatment of cervical low-grade squamous intraepithelial lesions with high-risk HPV infection: A retrospective study. ( Cheng, M; Di, W; Gu, L; Hong, Z; Qiu, L, 2021) |
| "Progression to high-grade squamous intraepithelial lesion warrants intervention." | 1.62 | The effect of local photodynamic therapy with 5-aminolevulinic acid for the treatment of cervical low-grade squamous intraepithelial lesions with high-risk HPV infection: A retrospective study. ( Cheng, M; Di, W; Gu, L; Hong, Z; Qiu, L, 2021) |
| "ALA-PDT is effective on treating hrHPV infection in patients with no cervical lesions." | 1.62 | Effectiveness of photodynamic therapy with 5-aminolevulinic acid on HPV clearance in women without cervical lesions. ( Cang, W; Di, W; Gu, L; Hong, Z; Qiu, L; Wu, A, 2021) |
| " Affecting factors of the efficacy of PDT and adverse events were also assessed during treatment." | 1.62 | Efficacy and safety of photodynamic therapy mediated by 5-aminolevulinic acid for the treatment of cervical intraepithelial neoplasia 2: A single-center, prospective, cohort study. ( Gao, X; Geng, L; Guo, H; Han, Q; Li, Y; Ma, L; Wang, Y; Wu, Z; You, K, 2021) |
| "PDT can be a safe and efficient treatment for CIN2." | 1.62 | Efficacy and safety of photodynamic therapy mediated by 5-aminolevulinic acid for the treatment of cervical intraepithelial neoplasia 2: A single-center, prospective, cohort study. ( Gao, X; Geng, L; Guo, H; Han, Q; Li, Y; Ma, L; Wang, Y; Wu, Z; You, K, 2021) |
| "80 patients with CINI and HR-HPV infection were selected for the study." | 1.56 | Treatment of HPV Infection-Associated Low Grade Cervical Intraepithelial Neoplasia with 5-Aminolevulinic Acid-Mediated Photodynamic Therapy. ( Cai, Q; Li, D; Lin, L; Shi, L; Xu, Y; Zhang, F, 2020) |
| "By co-culturing cervical cancer cell lines with immature DCs(imDCs) in the Transwell systems, we found that ALA-PDT induced HMGB1 exosomes could promote DCs maturation, which could be reversed by silencing HMGB1 in HPV-positive cervical cancer cells." | 1.48 | ALA-PDT promotes HPV-positive cervical cancer cells apoptosis and DCs maturation via miR-34a regulated HMGB1 exosomes secretion. ( Cao, P; Guan, Z; Jin, Y; Wang, X; Wang, Z; Xu, L; Zeng, R, 2018) |
| " In order to assist in optimizing treatment, we applied 5-ALA/PDT in combination with low-dose cisplatin to evaluate cytotoxicity in Hela cells." | 1.39 | Synergistic anticancer activity of 5-aminolevulinic acid photodynamic therapy in combination with low-dose cisplatin on Hela cells. ( Liu, AH; Ma, HQ; Wei, XQ; Zhang, YZ, 2013) |
| " In addition, it was confirmed that exposure of Hela cells to 5-ALA/PDT in combination with low-dose cisplatin resulted in more apoptosis in vitro." | 1.39 | Synergistic anticancer activity of 5-aminolevulinic acid photodynamic therapy in combination with low-dose cisplatin on Hela cells. ( Liu, AH; Ma, HQ; Wei, XQ; Zhang, YZ, 2013) |
| "Our findings suggest that administration of 5-ALA/PDT in combination with the low-dose cisplatin may be an effective and feasible therapy for cervical cancer." | 1.39 | Synergistic anticancer activity of 5-aminolevulinic acid photodynamic therapy in combination with low-dose cisplatin on Hela cells. ( Liu, AH; Ma, HQ; Wei, XQ; Zhang, YZ, 2013) |
| "After establishment of human cervical cancer xenograft model, the comparisons between 5-ALA-PDT with radiotherapy were performed with respect to treatment efficacies (survival rate, body weight, and tumor volume) and side effects (appearance and behavior, ovarian endocrine functions, and skin lesion around the tumor)." | 1.39 | Comparisons of 5-aminolevulinic acid photodynamic therapy and after-loading radiotherapy in vivo in cervical cancer. ( Cao, D; Gui, T; Liu, J; Mao, Y; Shen, K; Sun, S; Wang, Y; Yang, J, 2013) |
| "ALA-PDT is effective in treatment of cervical cancer." | 1.35 | [Effects of 5-aminolevulinic acid photodynamic therapy on cervical cancer: in vivo experiment with nude mice]. ( Bian, ML; He, GF; Li, HY; Xiang, Q; Xiao, C; Zhao, YW, 2008) |
| "The effect of ALA-PDT on apoptosis of cervical cancer cell line Me180 was investigated by using Annexin V-FITC/PI double staining, Hoechst 33342 staining and May-Grunwald-Farbstoff Giemsa staining." | 1.35 | [Apoptosis-inducing effect of 5-aminolevulinic acid-mediated photodynamic therapy (5-ALA-PDT) on cervical cancer cell lines]. ( Bian, ML; He, GF; Li, HY; Xiang, Q; Xiao, C; Zhao, YW, 2008) |
| " Therefore, lipophilic 5-ALA esters, such as hexylaminolevulinate (HAL), have led to improved local bioavailability and therapeutic efficacy." | 1.35 | Thermosetting gel for the delivery of 5-aminolevulinic acid esters to the cervix. ( Collaud, S; Gurny, R; Lange, N; Peng, Q, 2008) |
| "Two invasive cervical cancer cell lines were used, C33 and SIHA." | 1.29 | [The synergistic effect of delta-aminolevulinic acid and photodynamic laser therapy based on an in vitro model of the ATP tumor chemosensitivity test]. ( Hepp, H; Kirschstein, M; Korell, M; Untch, M, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (1.54) | 18.7374 |
| 1990's | 6 (9.23) | 18.2507 |
| 2000's | 16 (24.62) | 29.6817 |
| 2010's | 15 (23.08) | 24.3611 |
| 2020's | 27 (41.54) | 2.80 |
| Authors | Studies |
|---|---|
| Su, Y | 6 |
| Zhang, Y | 12 |
| Tong, Y | 1 |
| Zhang, L | 6 |
| Li, P | 1 |
| Zhang, H | 1 |
| Zhang, X | 2 |
| Tang, Y | 6 |
| Qin, L | 5 |
| Shen, Y | 5 |
| Wang, B | 5 |
| Zhou, Y | 6 |
| Cao, L | 5 |
| Zhang, M | 8 |
| Zhang, T | 6 |
| Hu, R | 1 |
| Wang, X | 6 |
| You, L | 1 |
| Zhang, W | 1 |
| Ma, Y | 1 |
| Xu, W | 1 |
| Xu, Y | 3 |
| Han, Q | 2 |
| Wu, Z | 2 |
| Guo, H | 2 |
| Cai, H | 2 |
| Che, Y | 2 |
| Sun, X | 1 |
| Yu, X | 1 |
| Yu, F | 1 |
| Hou, F | 1 |
| Wang, Y | 6 |
| Ma, T | 2 |
| Chen, F | 2 |
| Novák, Z | 1 |
| Dannecker, C | 2 |
| Mokráš, C | 1 |
| Sui, L | 2 |
| You, Z | 1 |
| Han, L | 1 |
| Lang, J | 1 |
| Hillemanns, P | 14 |
| Wang, L | 3 |
| Qiu, L | 4 |
| Li, J | 1 |
| Lv, Q | 1 |
| Li, C | 2 |
| Li, M | 1 |
| Yang, Q | 1 |
| Wu, D | 1 |
| Qie, M | 1 |
| Zhou, H | 1 |
| Zhou, J | 1 |
| Zhao, W | 1 |
| Xia, B | 1 |
| Liang, X | 1 |
| Cai, Y | 1 |
| Teng, Y | 2 |
| Huang, Z | 1 |
| Wei, L | 1 |
| Di, W | 4 |
| Liu, X | 2 |
| Zhang, J | 3 |
| Jia, L | 3 |
| Hu, Y | 1 |
| Li, Y | 2 |
| Chen, J | 2 |
| Ma, L | 2 |
| Qu, Z | 1 |
| Wang, Z | 2 |
| Qiu, S | 1 |
| Cui, G | 1 |
| Huang, Y | 1 |
| Liu, Y | 1 |
| Zhang, C | 1 |
| Zhou, M | 1 |
| Yuan, S | 1 |
| Huang, J | 1 |
| Wei, Y | 1 |
| Gu, L | 3 |
| Hong, Z | 3 |
| Zhao, X | 2 |
| Song, S | 1 |
| Mu, X | 1 |
| Hisamatsu, Y | 1 |
| Kita, M | 1 |
| Yokoe, T | 1 |
| Butsuhara, Y | 1 |
| Okada, H | 1 |
| Jiang, S | 1 |
| Nan, X | 1 |
| Pan, X | 1 |
| Tang, L | 1 |
| Gong, H | 1 |
| Yan, L | 1 |
| Ding, Z | 1 |
| Sun, H | 1 |
| de Castro, CA | 1 |
| Lombardi, W | 1 |
| Stringasci, MD | 1 |
| Bagnato, VS | 1 |
| Inada, NM | 1 |
| Li, D | 1 |
| Zhang, F | 1 |
| Shi, L | 1 |
| Lin, L | 1 |
| Cai, Q | 1 |
| Mizuno, M | 1 |
| Mitsui, H | 1 |
| Kajiyama, H | 1 |
| Teshigawara, T | 1 |
| Inoue, K | 1 |
| Takahashi, K | 1 |
| Ishii, T | 1 |
| Ishizuka, M | 1 |
| Nakajima, M | 1 |
| Kikkawa, F | 1 |
| Xu, J | 2 |
| Zhao, J | 1 |
| Dong, Y | 1 |
| Chen, R | 1 |
| Shi, Y | 1 |
| Tao, J | 1 |
| Cao, F | 1 |
| Cui, Y | 1 |
| Bai, W | 1 |
| Cheng, M | 1 |
| Cang, W | 1 |
| Wu, A | 1 |
| Gao, X | 2 |
| Geng, L | 1 |
| You, K | 1 |
| Jin, Y | 1 |
| Guan, Z | 1 |
| Zeng, R | 1 |
| Xu, L | 1 |
| Cao, P | 1 |
| Benito, M | 1 |
| Martín, V | 1 |
| Blanco, MD | 1 |
| Teijón, JM | 1 |
| Gómez, C | 1 |
| Wei, XQ | 1 |
| Ma, HQ | 1 |
| Liu, AH | 1 |
| Zhang, YZ | 1 |
| Vansevičiūtė, R | 1 |
| Venius, J | 1 |
| Letautienė, S | 1 |
| Garcia, F | 1 |
| Petry, KU | 1 |
| Dvorak, V | 1 |
| Sadovsky, O | 1 |
| Iversen, OE | 1 |
| Einstein, MH | 1 |
| Fu, Y | 1 |
| Bao, Y | 1 |
| Hui, Y | 1 |
| Yang, M | 1 |
| Chang, J | 1 |
| Guo, Q | 1 |
| Dong, B | 1 |
| Nan, F | 1 |
| Guan, D | 1 |
| Bae, SJ | 1 |
| Lee, DS | 1 |
| Berezin, V | 1 |
| Kang, U | 1 |
| Lee, KH | 1 |
| Hass, R | 1 |
| Jacobs, R | 1 |
| Kaufmann, AM | 1 |
| Soergel, P | 6 |
| He, GF | 3 |
| Bian, ML | 3 |
| Zhao, YW | 3 |
| Xiang, Q | 3 |
| Li, HY | 3 |
| Xiao, C | 3 |
| Stepp, H | 6 |
| Hertel, H | 3 |
| Szafińska-Dolata, A | 1 |
| Kedzia, W | 1 |
| Szafiński, A | 1 |
| Józefiak, A | 1 |
| Spaczyński, M | 1 |
| Wang, J | 1 |
| He, Q | 1 |
| Xiang, L | 1 |
| Huang, X | 1 |
| Ding, G | 1 |
| Xu, S | 1 |
| Loehr-Schulz, R | 1 |
| Hillemanns, M | 3 |
| Landwehr, S | 1 |
| Makowski, L | 2 |
| Makowski, E | 1 |
| Schippert, C | 1 |
| Dahl, GF | 1 |
| Onsrud, M | 1 |
| Gui, T | 1 |
| Mao, Y | 1 |
| Liu, J | 1 |
| Sun, S | 1 |
| Cao, D | 1 |
| Yang, J | 1 |
| Shen, K | 1 |
| Hiorth, M | 1 |
| Liereng, L | 1 |
| Reinertsen, R | 1 |
| Tho, I | 1 |
| Keefe, KA | 2 |
| Tadir, Y | 2 |
| Tromberg, B | 1 |
| Berns, M | 1 |
| Osann, K | 1 |
| Hashad, R | 1 |
| Monk, BJ | 1 |
| Barnett, AA | 1 |
| Haller, JC | 1 |
| Cairnduff, F | 1 |
| Lane, G | 1 |
| Brown, SB | 1 |
| Roberts, DJ | 1 |
| Andikyan, V | 2 |
| Kronschnabl, M | 1 |
| Andrejevic-Blant, S | 1 |
| Major, A | 1 |
| Lüdicke, F | 1 |
| Ballini, JP | 1 |
| Wagnières, G | 1 |
| van den Bergh, H | 1 |
| Pelte, MF | 1 |
| Sabban, F | 1 |
| Collinet, P | 1 |
| Cosson, M | 1 |
| Mordon, S | 1 |
| Collaud, S | 1 |
| Peng, Q | 2 |
| Gurny, R | 1 |
| Lange, N | 1 |
| Untch, M | 3 |
| Korell, M | 3 |
| Kirschstein, M | 2 |
| Hepp, H | 2 |
| Gaullier, JM | 1 |
| Berg, K | 1 |
| Anholt, H | 1 |
| Selbo, PK | 1 |
| Ma, LW | 1 |
| Moan, J | 1 |
| Martin-Hirsch, PL | 1 |
| Whitehurst, C | 1 |
| Buckley, CH | 1 |
| Moore, JV | 1 |
| Kitchener, HC | 1 |
| Pahernik, SA | 1 |
| Botzlar, A | 1 |
| Dellian, M | 1 |
| Abels, C | 1 |
| Mueller-Hoecker, J | 1 |
| Goetz, AE | 1 |
| Schmitt-Sody, M | 1 |
| Baumgartner, R | 3 |
| Beyer, W | 1 |
| Kimmig, R | 1 |
| Wierrani, F | 1 |
| Kubin, A | 1 |
| Jindra, R | 1 |
| Henry, M | 1 |
| Gharehbaghi, K | 1 |
| Grin, W | 1 |
| Söltz-Szötz, J | 1 |
| Alth, G | 1 |
| Grünberger, W | 1 |
| Weingandt, H | 2 |
| Diebold, J | 1 |
| Xiang, W | 2 |
| Chahine, EB | 1 |
| DiSaia, PJ | 1 |
| Krasieva, TB | 1 |
| Lin, F | 1 |
| Berns, MW | 1 |
| Liessmann, F | 1 |
| Klein, S | 1 |
| Bogaards, A | 1 |
| Aalders, MC | 1 |
| Zeyl, CC | 1 |
| de Blok, S | 1 |
| Sterenborg, HJ | 1 |
| Maruna, RF | 1 |
| Michalica, W | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Effect of 5-aminolaevulinic Acid Photodynamic Therapy Versus C02 Laser in the Treatment of Persistent Cervical Low-grade Squamous Intraepithelial Lesions With High-risk HPV Infection:A Non-randomized Controlled Trail Study[NCT06052033] | 40 participants (Anticipated) | Interventional | 2023-09-11 | Recruiting | |||
| A Double Blind, Prospective, Randomized, Placebo Controlled, Multi-center Phase 3 Study to Evaluate Efficacy and Safety of Cevira® in Patients With Cervical Histologic High-grade Squamous Intraepithelial Lesions (HSIL)[NCT04484415] | Phase 3 | 402 participants (Actual) | Interventional | 2020-11-10 | Active, not recruiting | ||
| A Randomized Phase II Dose-finding Study of Hexaminolevulinate (HAL) Photodynamic Therapy (PDT) in Patients With Low/Moderate-grade Cervical Intraepithelial Neoplasia (CIN1 or 2)[NCT01256424] | Phase 2 | 262 participants (Actual) | Interventional | 2011-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
HPV response was defined as clearance of baseline HPV infection, asssessed by genotype (NCT01256424)
Timeframe: 3 months after treatment
| Intervention | percentage of patients (Number) |
|---|---|
| HAL 5% With Illumination | 62 |
| HAL 1% With Illumination | 38 |
| HAL 0.2% With Illumination | 41 |
| Placebo Ointment Without Illumination | 28 |
Lesion response was defined by three variables: Histology, cytology and HPV. Patient response at three months required histology regression to CIN1 or normal, cytology of LSIL or less severe, and HPV negative. (NCT01256424)
Timeframe: 3 months after last treatment
| Intervention | percentage of patients (Number) |
|---|---|
| HAL 5% With Illumination | 95 |
| HAL 1% With Illumination | 69 |
| HAL 0.2% With Illumination | 63 |
| Placebo Ointment Without Illumination | 57 |
Response was defined as absence of HSIL, and absence of oncogenic HPV if LSIL. (NCT01256424)
Timeframe: 6 months after first treatment
| Intervention | percentage of participants (Number) |
|---|---|
| HAL 5% With Illumination | 76 |
| HAL 1% With Illumination | 45 |
| HAL 0.2% With Illumination | 43 |
| Placebo Ointment Without Illumination | 28 |
Response was defined as absence of HSIL, and absence of oncogenic HPF if LSIL (NCT01256424)
Timeframe: 9 months after first treatment
| Intervention | percentage of participants (Number) |
|---|---|
| HAL 5% With Illumination | 76 |
| HAL 1% With Illumination | 50 |
| HAL 0.2% With Illumination | 43 |
| Placebo Ointment Without Illumination | 33 |
3 reviews available for aminolevulinic acid and Cancer of Cervix
| Article | Year |
|---|---|
Chinese expert consensus on the clinical applications of aminolevulinic acid-based photodynamic therapy in female lower genital tract diseases (2022).
Topics: Aminolevulinic Acid; Female; Genitalia; Humans; Photochemotherapy; Photosensitizing Agents; Pregnanc | 2022 |
5-Aminolevulinic acid-based fluorescence diagnostics of cervical preinvasive changes.
Topics: Aminolevulinic Acid; Female; Fluorescence; Humans; Photosensitizing Agents; Protoporphyrins; Sensiti | 2014 |
[Fluorescence imaging technique: diagnostic and therapeutic interest in gynecology].
Topics: Aminolevulinic Acid; Breast Neoplasms; Female; Genital Diseases, Female; Gynecology; Humans; Neoplas | 2004 |
13 trials available for aminolevulinic acid and Cancer of Cervix
| Article | Year |
|---|---|
Multicentre, prospective, randomised controlled trial to evaluate hexaminolevulinate photodynamic therapy (Cevira) as a novel treatment in patients with high-grade squamous intraepithelial lesion: APRICITY phase 3 study protocol.
Topics: Aminolevulinic Acid; Carcinoma in Situ; Clinical Trials, Phase III as Topic; Female; Humans; Multice | 2022 |
The effect of aminolevulinic acid hydrochloride topical powder photodynamic therapy versus nocardia rubra cell wall skeleton and observers group in the treatment of cervical low-grade squamous intraepithelial lesions with human papillomavirus infection: A
Topics: Aminolevulinic Acid; Cell Wall Skeleton; Female; Human Papillomavirus Viruses; Humans; Papillomaviru | 2023 |
A randomized study of hexaminolevulinate photodynamic therapy in patients with cervical intraepithelial neoplasia 1/2.
Topics: Administration, Topical; Adolescent; Adult; Aminolevulinic Acid; Dose-Response Relationship, Drug; D | 2015 |
Topical photodynamic therapy with 5-aminolevulinic acid for cervical high-risk HPV infection.
Topics: Administration, Topical; Adult; Aminolevulinic Acid; Female; Humans; Middle Aged; Papillomavirus Inf | 2016 |
Photodynamic therapy of cervical intraepithelial neoplasia with hexaminolevulinate.
Topics: Adult; Aminolevulinic Acid; Feasibility Studies; Female; Humans; Papillomavirus Infections; Photoche | 2008 |
Effects of photodynamic therapy using topical applied hexylaminolevulinate and methylaminolevulinate upon the integrity of cervical epithelium.
Topics: Administration, Topical; Adult; Aminolevulinic Acid; Biomarkers, Tumor; Cohort Studies; Double-Blind | 2010 |
Photodynamic therapy of cervical intraepithelial neoplasia 1-3 and human papilloma virus (HMV) infection with methylaminolevulinate and hexaminolevulinate--a double-blind, dose-finding study.
Topics: Adult; Aminolevulinic Acid; Double-Blind Method; Female; Humans; Papillomavirus Infections; Photoche | 2012 |
Photodynamic therapy of high-grade cervical intraepithelial neoplasia with 5-aminolevulinic acid.
Topics: Adult; Aminolevulinic Acid; Female; Follow-Up Studies; Humans; Outcome Assessment, Health Care; Phot | 2002 |
A randomised, double-blind, placebo-controlled trial of photodynamic therapy using 5-aminolaevulinic acid for the treatment of cervical intraepithelial neoplasia.
Topics: Administration, Topical; Adult; Aminolevulinic Acid; Cervix Uteri; Colposcopy; Double-Blind Method; | 2003 |
Photodynamic therapy in women with cervical intraepithelial neoplasia using topically applied 5-aminolevulinic acid.
Topics: Administration, Topical; Aminolevulinic Acid; Colposcopy; Female; Humans; Image Processing, Computer | 1999 |
5-aminolevulinic acid-mediated photodynamic therapy of intraepithelial neoplasia and human papillomavirus of the uterine cervix--a new experimental approach.
Topics: Administration, Intravaginal; Adolescent; Adult; Aminolevulinic Acid; Combined Modality Therapy; Dru | 1999 |
Photodetection of cervical intraepithelial neoplasia using 5-aminolevulinic acid-induced porphyrin fluorescence.
Topics: Adult; Aminolevulinic Acid; Female; Humans; Photosensitizing Agents; Porphyrins; Sensitivity and Spe | 2000 |
Fluorescence detection of cervical intraepithelial neoplasia for photodynamic therapy with the topical agents 5-aminolevulinic acid and benzoporphyrin-derivative monoacid ring.
Topics: Absorption; Aminolevulinic Acid; Cervix Uteri; Female; Humans; Microscopy, Fluorescence; Photochemot | 2001 |
49 other studies available for aminolevulinic acid and Cancer of Cervix
| Article | Year |
|---|---|
Effect and rational application of topical photodynamic therapy (PDT) with 5-aminolevulinic acid (5-ALA) for treatment of cervical intraepithelial neoplasia with vaginal intraepithelial neoplasia.
Topics: Aminolevulinic Acid; Female; Human papillomavirus 16; Human papillomavirus 18; Humans; Papillomaviru | 2022 |
The effect of local photodynamic therapy with 5-aminolevulinic acid in the treatment of vaginal intraepithelial lesions with high-risk HPV infection.
Topics: Aminolevulinic Acid; Female; Human papillomavirus 16; Human papillomavirus 18; Humans; Neoplasm Recu | 2022 |
Evaluation of 5-aminolevulinic acid-mediated photodynamic therapy on cervical low-grade squamous intraepithelial lesions with high-risk HPV infection.
Topics: Aminolevulinic Acid; Cervix Uteri; Ectropion; Female; Humans; Papillomavirus Infections; Photochemot | 2022 |
Therapeutic effects of topical photodynamic therapy with 5-aminolevulinic acid on cervical high-grade squamous intraepithelial lesions.
Topics: Adolescent; Adult; Aminolevulinic Acid; Carcinoma, Squamous Cell; Female; Humans; Middle Aged; Papil | 2022 |
Efficacy and safety of photodynamic therapy mediatied by 5-aminolevulinic acid for the treatment of vaginal high-grade intraepithelial lesions.
Topics: Aminolevulinic Acid; Carcinoma in Situ; Female; Humans; Papillomaviridae; Papillomavirus Infections; | 2022 |
Clinical outcome of photodynamic therapy for the treatment of cervical intraepithelial neoplasia grade 2.
Topics: Aminolevulinic Acid; Female; Humans; Papillomavirus Infections; Photochemotherapy; Photosensitizing | 2022 |
The effect of high-risk HPV E6/E7 mRNA on the efficacy of topical photodynamic therapy with 5-aminolevulinic acid for cervical high-grade squamous intraepithelial lesions.
Topics: Aminolevulinic Acid; Female; Human papillomavirus 16; Human papillomavirus 18; Humans; Neoplasm Recu | 2022 |
Management of patients with positive margin after conization for high-grade cervical intraepithelial lesions.
Topics: Aminolevulinic Acid; Conization; Female; Humans; Margins of Excision; Neoplasm Recurrence, Local; Pa | 2022 |
Evaluation of 5-aminolevulinic acid-mediated photodynamic therapy in postmenopausal women with persistent HPV infection with or without cervical and vaginal low-grade squamous intraepithelial lesions (CIN1/VaIN1).
Topics: Aminolevulinic Acid; Female; Humans; Papillomaviridae; Papillomavirus Infections; Photochemotherapy; | 2022 |
Topical 5-aminolevulinic acid photodynamic therapy for cervical high-grade squamous intraepithelial lesions.
Topics: Aminolevulinic Acid; Female; Humans; Papillomaviridae; Papillomavirus Infections; Photochemotherapy; | 2022 |
Efficacy of photodynamic therapy with 5-aminolevulinic acid for the treatment of cervical high-grade squamous intraepithelial lesions with high-risk HPV infection: A retrospective study.
Topics: Aminolevulinic Acid; Female; Humans; Papillomavirus Infections; Photochemotherapy; Retrospective Stu | 2022 |
Evaluation of the efficacy and safety of 5-aminolevulinic acid-mediated photodynamic therapy in women with high-risk HPV persistent infection after cervical conization.
Topics: Aminolevulinic Acid; Conization; Female; Human papillomavirus 16; Human papillomavirus 18; Humans; M | 2022 |
The effect of local photodynamic therapy with 5-aminolevulinic acid in treating different grades of cervical intraepithelial neoplasia.
Topics: Aminolevulinic Acid; Female; Humans; Neoplasm Recurrence, Local; Papillomavirus Infections; Photoche | 2022 |
Feasibility study of 5-aminolevulinic acid mediated photodynamic therapy of persistent vaginal high-risk HPV infection of post-hysterectomy patients.
Topics: Adult; Aged; Aminolevulinic Acid; Feasibility Studies; Female; Humans; Hysterectomy; Middle Aged; Pa | 2023 |
Effects of photodynamic therapy in the treatment of high-grade vaginal intraepithelial lesions following hysterectomy and HPV infection.
Topics: Aminolevulinic Acid; Female; Humans; Hysterectomy; Papillomavirus Infections; Photochemotherapy; Pho | 2023 |
A pilot study of repeated 5-aminolevulinic acid photodynamic therapy for cervical intraepithelial neoplasia by a newly developed intravaginal irradiation system.
Topics: Aminolevulinic Acid; Female; Humans; Papillomavirus Infections; Photochemotherapy; Photosensitizing | 2023 |
Application of 5-aminolevulinic acid photodynamic therapy for vaginal intraepithelial neoplasia, a report of six cases.
Topics: Aminolevulinic Acid; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Papillomavirus Infecti | 2020 |
High-risk HPV clearance and CIN 3 treated with MAL-PDT: A case report.
Topics: Adult; Aminolevulinic Acid; Female; Humans; Neoplasm Recurrence, Local; Papillomavirus Infections; P | 2020 |
Treatment of HPV Infection-Associated Low Grade Cervical Intraepithelial Neoplasia with 5-Aminolevulinic Acid-Mediated Photodynamic Therapy.
Topics: Adult; Aminolevulinic Acid; Female; Humans; Papillomavirus Infections; Photochemotherapy; Photosensi | 2020 |
Efficacy of 5-aminolevulinic acid and LED photodynamic therapy in cervical intraepithelial neoplasia: A clinical trial.
Topics: Aminolevulinic Acid; Female; Humans; Neoplasm Recurrence, Local; Photochemotherapy; Photosensitizing | 2020 |
Photodetection and Safety of 5-Aminolevulinic Acid-Induced Porphyrin in Patients With Cervical Intraepithelial Neoplasia.
Topics: Aminolevulinic Acid; Female; Humans; Porphyrins; Retrospective Studies; Uterine Cervical Dysplasia; | 2021 |
The effect of local photodynamic therapy with 5-aminolevulinic acid for the treatment of cervical low-grade squamous intraepithelial lesions with high-risk HPV infection: A retrospective study.
Topics: Adult; Aged; Aminolevulinic Acid; Female; Human papillomavirus 16; Human papillomavirus 18; Humans; | 2021 |
Effectiveness of photodynamic therapy with 5-aminolevulinic acid on HPV clearance in women without cervical lesions.
Topics: Aminolevulinic Acid; Female; Human papillomavirus 16; Human papillomavirus 18; Humans; Papillomaviru | 2021 |
Efficacy and safety of photodynamic therapy mediated by 5-aminolevulinic acid for the treatment of cervical intraepithelial neoplasia 2: A single-center, prospective, cohort study.
Topics: Aminolevulinic Acid; Cohort Studies; Female; Humans; Photochemotherapy; Photosensitizing Agents; Pro | 2021 |
ALA-PDT promotes HPV-positive cervical cancer cells apoptosis and DCs maturation via miR-34a regulated HMGB1 exosomes secretion.
Topics: Aminolevulinic Acid; Apoptosis; Cell Line, Tumor; Exosomes; Female; HMGB1 Protein; Human papillomavi | 2018 |
Cooperative effect of 5-aminolevulinic acid and gold nanoparticles for photodynamic therapy of cancer.
Topics: Aminolevulinic Acid; Apoptosis; Cell Death; Cell Line, Tumor; Cervix Uteri; Drug Synergism; Female; | 2013 |
Synergistic anticancer activity of 5-aminolevulinic acid photodynamic therapy in combination with low-dose cisplatin on Hela cells.
Topics: Aminolevulinic Acid; Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Blotting, Western | 2013 |
5-Aminolevulinic acid photodynamic therapy in human cervical cancer via the activation of microRNA-143 and suppression of the Bcl-2/Bax signaling pathway.
Topics: Aminolevulinic Acid; Apoptosis; bcl-2-Associated X Protein; Cell Proliferation; Down-Regulation; Fem | 2016 |
Multispectral autofluorescence imaging for detection of cervical lesions: A preclinical study.
Topics: Aminolevulinic Acid; Animals; Cell Line, Tumor; Disease Models, Animal; Female; Human papillomavirus | 2016 |
Sensitization of immune cells following hexylaminolevulinate photodynamic therapy of cervical intraepithelial neoplasia.
Topics: Aminolevulinic Acid; CD4-CD8 Ratio; Cell Cycle; Female; Human papillomavirus 16; Humans; Leukocytes, | 2017 |
[Effects of 5-aminolevulinic acid photodynamic therapy on cervical cancer: in vivo experiment with nude mice].
Topics: Aminolevulinic Acid; Animals; Apoptosis; Cell Line, Tumor; Female; Humans; Immunohistochemistry; Mic | 2008 |
[Apoptosis-inducing effect of 5-aminolevulinic acid-mediated photodynamic therapy (5-ALA-PDT) on cervical cancer cell lines].
Topics: Aminolevulinic Acid; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Female; Humans; In | 2008 |
A study on the mechanism of 5-aminolevulinic acid photodynamic therapy in vitro and in vivo in cervical cancer.
Topics: Aminolevulinic Acid; Animals; Apoptosis; Cell Line, Tumor; Female; Humans; Mice; Mice, Inbred BALB C | 2009 |
[Comparison of sensitivity and specificity of PDD, colposcopy and cytology in the detection of cervical neoplastic lesions].
Topics: Adult; Aminolevulinic Acid; Cervix Uteri; Colposcopy; Cytological Techniques; Female; Fluorescence; | 2009 |
Successful photodynamic therapy with topical 5-aminolevulinic acid for five cases of cervical intraepithelial neoplasia.
Topics: Administration, Topical; Adult; Aminolevulinic Acid; Female; Humans; Middle Aged; Papillomavirus Inf | 2010 |
Treatment of high grade cervical intraepithelial neoplasia by photodynamic therapy using hexylaminolevulinate may be costeffective compared to conisation procedures due to decreased pregnancy-related morbidity.
Topics: Aminolevulinic Acid; Cervix Uteri; Conization; Cost-Benefit Analysis; Female; Germany; Health Care C | 2011 |
Comparisons of 5-aminolevulinic acid photodynamic therapy and after-loading radiotherapy in vivo in cervical cancer.
Topics: Aminolevulinic Acid; Animals; Apoptosis; Blotting, Western; Cell Proliferation; Female; HeLa Cells; | 2013 |
Formulation of bioadhesive hexylaminolevulinate pellets intended for photodynamic therapy in the treatment of cervical cancer.
Topics: Acrylates; Adhesiveness; Aminolevulinic Acid; Animals; Cattle; Drug Delivery Systems; Drug Stability | 2013 |
[Fluorescence diagnosis with 5-ALA thermogel of cervical intraepithelial neoplasia].
Topics: Adult; Aminolevulinic Acid; Biopsy; Cervix Uteri; Conization; Data Interpretation, Statistical; Fema | 2004 |
Time-dependent hexaminolaevulinate induced protoporphyrin IX distribution after topical application in patients with cervical intraepithelial neoplasia: A fluorescence microscopy study.
Topics: Administration, Topical; Adult; Aminolevulinic Acid; Female; Humans; Microscopy, Fluorescence; Middl | 2004 |
Thermosetting gel for the delivery of 5-aminolevulinic acid esters to the cervix.
Topics: Administration, Cutaneous; Aminolevulinic Acid; Animals; Cervix Uteri; Drug Carriers; Female; Hydrog | 2008 |
Pharmacokinetics and selectivity of porphyrin synthesis after topical application of hexaminolevulinate in patients with cervical intraepithelial neoplasia.
Topics: Administration, Topical; Adult; Aminolevulinic Acid; Carbon Radioisotopes; Female; Fluorescence; Hum | 2008 |
[The synergistic effect of delta-aminolevulinic acid and photodynamic laser therapy based on an in vitro model of the ATP tumor chemosensitivity test].
Topics: Adenosine Triphosphate; Aminolevulinic Acid; Carcinoma, Squamous Cell; Cell Line; Cell Survival; Dos | 1995 |
Use of 5-aminolevulinic acid esters to improve photodynamic therapy on cells in culture.
Topics: Adenocarcinoma; Aminolevulinic Acid; Animals; Colonic Neoplasms; Cricetinae; Cricetulus; Drug Screen | 1997 |
Photodynamic treatment for lower genital tract intraepithelial neoplasia.
Topics: Aminolevulinic Acid; Carcinoma in Situ; Female; Humans; Photochemotherapy; Photosensitizing Agents; | 1998 |
Pharmacokinetics and selectivity of aminolevulinic acid-induced porphyrin synthesis in patients with cervical intra-epithelial neoplasia.
Topics: Adult; Aminolevulinic Acid; Cervix Uteri; Conization; Epithelial Cells; Female; Humans; Microscopy, | 1998 |
Photodynamic effects induced by aminolevulinic acid esters on human cervical carcinoma cells in culture.
Topics: Aminolevulinic Acid; Annexin A5; Apoptosis; Carcinoma in Situ; Cell Membrane; Cell Survival; Dose-Re | 2001 |
Localization and staging of cervical intraepithelial neoplasia using double ratio fluorescence imaging.
Topics: Adult; Aminolevulinic Acid; Colposcopy; Female; Humans; Middle Aged; Monte Carlo Method; Neoplasm St | 2002 |
[Excretion of delta-aminolevulinic acid during combined radiotherapy of patients with cervix carcinoma. 2. Medical check-ups for lead in the Vienna area among various occupational and personal groups].
Topics: Aminolevulinic Acid; Bone and Bones; Cobalt Radioisotopes; Extracorporeal Circulation; Female; Human | 1975 |